Skip to main content
. 2014 Sep 10;5(19):8924–8936. doi: 10.18632/oncotarget.2441

Figure 1. Cell Viablility Assay for five demethylation drugs in MEFs.

Figure 1

(A) Molecular structures of five DNA methylation inhibitors. Nucleoside analogues (a-c) and Non-nucleoside analogues (d,e). (B) Cell relative survival plot by Guava assay of 5 demethylation agents in primary MEF cells (P0-P2). FCDR (5-fluoro-20-deoxycytidine); Decitabine (5-aza-2-deoxycytidine); Zebularine (1-beta-D-ribofluranosyl-2(1H)-pyrimidinone); EGCG (-)-epigarllocatechin-3-gallate; RG108 (N-Phthalyl-L-Tryptophan); P53wt (brown, cycle); p53KO(red, square); p53R172H(blue, triangle) & p53R270H(green, diamond).